GlaxoSmithKline PLC
13 April 2005
Director's Interests
I give below details of changes in interests in the Ordinary Shares and American
Depositary Receipts (ADRs) of GlaxoSmithKline plc in respect of the
under-mentioned directors:-
Dr J P Garnier The Administrators of the GlaxoSmithKline Performance
Share Plan notified the Company and Dr Garnier on
13 April 2005 that his interest had notionally
increased by 3819.757 ADRs at a price of $47.43 per ADR
following the notional re-investment of the dividend
paid to shareholders on 07 April 2005.
Dr T Yamada The Administrators of the GlaxoSmithKline Performance
Share Plan notified the Company and Dr Yamada on
13 April 2005 that his interest had notionally
increased by 1145.928 ADRs at a price of $47.43 per ADR
following the notional re-investment of the dividend
paid to shareholders on 07 April 2005.
Mr J S Heslop The Administrators of the GlaxoSmithKline Performance
Share Plan notified the Company and Mr Heslop on
13 April 2005 that his interest had notionally
increased by 148.919 Ordinary Shares at a price of
£12.49 per Ordinary Share following the notional
re-investment of the dividend paid to shareholders on
07 April 2005.
The notional dividends accrued will be paid out in proportion to the percentage
of participants' Performance Share Plan holdings that vest following the end of
the relevant three year measurement period.
S M Bicknell
Company Secretary
13 April 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.